Page last updated: 2024-12-11

nuezhenide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

nuezhenide: from Ligustrum lucidum; structure given in first source; RN refers to trans-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
LigustrumgenusA plant genus of the family OLEACEAE. Oleuropein, a phenolic secoiridoid glycoside, is found in the leaves.[MeSH]OleaceaeA plant family of the order Lamiales. The leaves are usually opposite and the flowers usually have four sepals, four petals, two stamens, and two fused carpels that form a single superior ovary.[MeSH]

Cross-References

ID SourceID
PubMed CID6440999
CHEMBL ID1076818
MeSH IDM0221385

Synonyms (10)

Synonym
specnuezhenide
CHEMBL1076818
nuzhenide
nuezhenide
methyl (5e,6s)-5-ethylidene-4-[2-oxo-2-[[(2r,3s,4s,5r,6r)-3,4,5-trihydroxy-6-[2-(4-hydroxyphenyl)ethoxy]oxan-2-yl]methoxy]ethyl]-6-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4h-pyran-3-carboxylate
39011-92-2
2-(4-hydroxyphenyl)ethyl-6-(3-ethylidene-2-(beta-d-glucopyranosyloxyl)-3,4-dihydro-5-(methoxycarbonyl)-2h-pyran-4-acetate)-beta-d-glucopyranoside
beta-d-glucopyranoside, 2-(4-hydroxyphenyl)ethyl, 6-(3-ethylidene-2-(beta-d-glucopyranosyloxy)-3,4-dihydro-5-(methoxycarbonyl)-2h-pyran-4-acetate), trans-
S9473
AKOS032948815

Research Excerpts

Overview

Specnuezhenide (SPZ) is a characteristic active component of Ligustrum lucidum. It exerts a variety of pharmacological effects.

ExcerptReferenceRelevance
"Specnuezhenide (SPZ) is a characteristic active component of Ligustrum lucidum, a plant which exerts a variety of pharmacological effects."( Protective effect of Specnuezhenide on islet β cell of rats with gestational diabetes mellitus.
Jia, J; Li, Q; Yang, J; Yang, Y; Zhao, Y, 2020
)
1.34

Pharmacokinetics

ExcerptReferenceRelevance
" This study was successfully utilized for the pharmacokinetic study of specnuezhenide in rats after oral and intravenous administration."( A validated LC-MS/MS method for the determination of specnuezhenide and salidroside in rat plasma and its application to a pharmacokinetic study.
Ding, Y; Ju, Z; Ma, C, 2018
)
0.96

Bioavailability

ExcerptReferenceRelevance
" The results were verified by measuring the absolute bioavailability of the active ingredients."( Analysis of five active ingredients of Er-Zhi-Wan, a traditional Chinese medicine water-honeyed pill, using the biopharmaceutics classification system.
Cao, X; Deng, Y; Li, H; Ren, X; Wang, M, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
saccharolipid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID466886Activation of PPARalpha transfected into HEK cells at 100 uM by luciferase assay2010Journal of natural products, Jan, Volume: 73, Issue:1
Iridoids from Fraxinus excelsior with adipocyte differentiation-inhibitory and PPARalpha activation activity.
AID466891Inhibition of GLUT42010Journal of natural products, Jan, Volume: 73, Issue:1
Iridoids from Fraxinus excelsior with adipocyte differentiation-inhibitory and PPARalpha activation activity.
AID466879Inhibition of adipocyte differentiation in mouse 3T3L1 cells assessed as inhibition of 2 deoxy-D[3H]glucose uptake at 0.05 mg/ml after 15 mins by scintillation counter relative to control2010Journal of natural products, Jan, Volume: 73, Issue:1
Iridoids from Fraxinus excelsior with adipocyte differentiation-inhibitory and PPARalpha activation activity.
AID466881Inhibition of adipocyte differentiation in mouse 3T3L1 cells assessed as inhibition of 2 deoxy-D[3H]glucose uptake at 0.5 mg/ml after 15 mins by scintillation counter relative to control2010Journal of natural products, Jan, Volume: 73, Issue:1
Iridoids from Fraxinus excelsior with adipocyte differentiation-inhibitory and PPARalpha activation activity.
AID466882Inhibition of adipocyte differentiation in mouse 3T3L1 cells assessed as inhibition of 2 deoxy-D[3H]glucose uptake at 1 mg/ml after 15 mins by scintillation counter relative to control2010Journal of natural products, Jan, Volume: 73, Issue:1
Iridoids from Fraxinus excelsior with adipocyte differentiation-inhibitory and PPARalpha activation activity.
AID466880Inhibition of adipocyte differentiation in mouse 3T3L1 cells assessed as inhibition of 2 deoxy-D[3H]glucose uptake at 0.2 mg/ml after 15 mins by scintillation counter relative to control2010Journal of natural products, Jan, Volume: 73, Issue:1
Iridoids from Fraxinus excelsior with adipocyte differentiation-inhibitory and PPARalpha activation activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (20)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (15.00)18.2507
2000's0 (0.00)29.6817
2010's10 (50.00)24.3611
2020's7 (35.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.69

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.69 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index5.78 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.69)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]